Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies

References

• WieldersLHLambermontVASchoutenJSPrevention of cystoid macular edema after cataract surgery in non-diabetic and diabetic patients: a systematic review and meta-analysisAm J Ophthalmol2015160596898126232601
   PubMed Web of Science ®Google Scholar
• KimSJSchoenbergerSDThorneJEEhlersJPYehSBakriSJTopical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of OphthalmologyOphthalmology2015122112159216826123091
   PubMed Web of Science ®Google Scholar
• HendersonBAKimJYAmentCSFerrufino-PonceZKGrabowskaACremersSLClinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatmentJ Cataract Refract Surg20073391550155817720069
   PubMed Web of Science ®Google Scholar
• BenitahNRArroyoJGPseudophakic cystoid macular edemaInt Ophtalmol Clin2010501139153
   PubMedGoogle Scholar
• ErikssonUAlmABjarnhallGGranstamEMatssonAWMacular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controlsGraefes Arch Clin Exp Ophthalmol2011249334935920827486
   PubMed Web of Science ®Google Scholar
• KreplerKBiowskiRSchreySJandrasitsKWedrichACataract surgery in patients with diabetic retinopathy: visual outcome, progres sion of diabetic retinopathy, and incidence of diabetic macular oedemaGraefes Arch Clin Exp Ophthalmol2002240973573812271370
   PubMed Web of Science ®Google Scholar
• BakerCWAlmukhtarTBresslerNMDiabetic Retinopathy Clinical Research Network Authors/Writing CommitteeMacular edema after cataract surgery in eyes without preoperative central involved diabetic macular edemaJAMA Ophthalmol2013131787087923599174
   PubMed Web of Science ®Google Scholar
• DowlerJGFSehmiKSHykinPGHamiltonAMThe natural history of macular edema after cataract surgery in diabetesOphthalmology1999106466366810201584
   PubMed Web of Science ®Google Scholar
• ChuCJJohnstonRLBuscombeCSallamABMohamedQYangYCUnited Kingdom Pseudophakic Macular Edema Study Group OphthalmologyRisk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyesOphthalmology2016123231632326681390
   PubMed Web of Science ®Google Scholar
• RossettiLChaudhuriJDickersinKMedical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysisOphthalmology199810533974059499767
   PubMed Web of Science ®Google Scholar
• KesselLTendalBJørgensenKJPost-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic reviewOphthalmology2014121101915192424935281
   PubMed Web of Science ®Google Scholar
• European Medical Agency Assessment Report: Nevenac EMA/CHMP/167525/2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000818/WC500212717.pdfAccessed October 5, 2016
   Google Scholar
• ILEVRO^™ (nepafenac ophthalmic suspension 0.3%) [package insert]Fort Worth, TXAlcon Laboratories, Inc2014 Available from: http://ecatalog.alcon.com/PI/Ilevro_us_en.pdfAccessed April 27, 2016
   Google Scholar
• KeTLGraffGSpellmanJMYanniJMNepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation200024437138410850858
   PubMed Web of Science ®Google Scholar
• WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
   PubMed Web of Science ®Google Scholar
• ChastainJESandersMECurtisMADistribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eyeExp Eye Res2016145586726474497
   PubMed Web of Science ®Google Scholar
• SinghRAlpernLJaffeGJEvaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathyClin Ophthalmol201261259126922927737
   PubMedGoogle Scholar
• PollackAStaurenghiGSagerDMukeshBReiserHSinghRProspective randomized clinical trial to evaluate the safety and efficacy of nepafenac treatment for the prevention of macular edema associated with cataract surgery in patients with diabetic retinopathyBr J Ophthalmol20161527378485
   PubMed Web of Science ®Google Scholar
• SinghRLehmannRMartelJNepafenac 0.3% following cataract surgery in patients with diabetic retinopathy: results of two randomized Phase 3 studiesOphthalmology Epub201734
   Web of Science ®Google Scholar
• MiyakeKOtaIMiyakeGNumagaJNepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgeryJ Cataract Refract Surg20113791581158821855758
   PubMed Web of Science ®Google Scholar
• HariprasadSMCallananDGaineySHeYGWarrenKCystoid and diabetic macular edema treated with nepafenac 0.1%J Ocul Pharmacol Ther200723658559018001248
   PubMed Web of Science ®Google Scholar
• American Medical Association2016Registry Individual Measure Flow-Measure #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery – National Quality Strategy Domain: Effective Clinical Care Available from: http://www.mdinteractive.com/files/uploaded/file/CMS2016/2016_PQRS_Measure_191_11_17_2015.pdfAccessed on May 6, 2016
   Google Scholar
• MittraRABorrilloJLDevSMielerWFKoenigSBRetinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitusArch Ophthalmol2000118791291710900103
   PubMedGoogle Scholar
• BakerCWAlmukhtarTBresslerNMMacular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edemaJAMA Ophthalmol2013131787087923599174
   PubMed Web of Science ®Google Scholar
• LundströmMManningSBarryPSteneviUHenryYRosenPVisual outcome of cataract surgery; study from the European registry of quality outcomes for cataract and refractive surgeryJ Cataract Refract Surg201339567367923499065
   PubMed Web of Science ®Google Scholar
• MorrisDFraserSDGrayCCataract surgery and quality of life implicationsClin Interv Aging20072110510818044082
   PubMed Web of Science ®Google Scholar
• FergusonVMGSpaltonDJContinued breakdown of the blood aqueous barrier following cataract surgeryBr J Ophthalmol19927684534561390524
   PubMed Web of Science ®Google Scholar
• PollackALeibaHBukelmanAOliverMCystoid macular oedema following cataract extraction in patients with diabetesBr J Ophthalmol19927642212241390489
   PubMed Web of Science ®Google Scholar
• HenricssonMHeijlAJanzonLDiabetic retinopathy before and after cataract surgeryBr J Ophthalmol19968097897938942374
   PubMed Web of Science ®Google Scholar
• ZaczekAOlivestedtGZetterstromCVisual outcome after phacoemulsification and IOL implantation in diabetic patientsBr J Ophthalmol19998391036104110460771
   PubMed Web of Science ®Google Scholar
• WolfEJBraunsteinAShihCBraunsteinREIncidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJ Cataract Refract Surg20073391546154917720068
   PubMed Web of Science ®Google Scholar
• MathysKCCohenKLImpact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedemaEye (Lond)2010241909619229275
   PubMed Web of Science ®Google Scholar
• AlmeidaDRPKhanZXingLProphylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsificationJ Cataract Refract Surg20123891537154322795976
   PubMed Web of Science ®Google Scholar
• TzelikisPFVieiraMHidaWtComparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised studyBr J Ophthalmol201599565465825385061
   PubMed Web of Science ®Google Scholar
• AlmeidaDRPJohnsonDHollandsHEffect of prophylactic nonsteroidal anti-inflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgeryJ Cataract Refract Surg2008341646918165083
   PubMed Web of Science ®Google Scholar
• AsanoSMiyakeKOtaIReducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%J Cataract Refract Surg2008341576318165082
   PubMed Web of Science ®Google Scholar
• HirneissCNeubauerASKampikASchonfeldCLComparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked studyGraefes Arch Clin Exp Ophthalmol2005243876877315756571
   PubMed Web of Science ®Google Scholar
• HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked studyJ Cataract Refract Surg2002281939911777716
   PubMed Web of Science ®Google Scholar
• WangQWYaoKXuWBromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsificationOphthalmologica2013229418719423429038
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDHollandEJSolomonKDA multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgeryAm J Ophthalmol2011152460961721704965
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDPerryHDWittpennJRSolomonRNattisAChouTPreoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic response curveJ Cataract Refract Surg20063291474148216931258
   PubMed Web of Science ®Google Scholar